Biosimilars: comparative efficacy trials under the spotlight
Debate is intensifying over the regulatory hurdles that biosimilar manufacturers should have to jump to get their products to market, and the ultimate impact on access to medicines.
Debate is intensifying over the regulatory hurdles that biosimilar manufacturers should have to jump to get their products to market, and the ultimate impact on access to medicines.